This website is dedicated to providing UK and Ireland healthcare professionals with up-to-date information on the management of refractory focal epilepsy in adults. This is a promotional website managed and funded by Angelini Pharma.
This promotional website is managed and funded by Angelini Pharma and is intended for UK and Ireland healthcare professionals only.
Expert insights from Professor John Paul Leach on epilepsy management.
For materials designed to support healthcare professionals and their patients.
United Kingdom: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti–epileptic medicinal products.1
Republic of Ireland: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti–epileptic medicinal products.1
1. ONTOZRY® Summary of Product Characteristics. United Kingdom and European Union.
MAT-UKI-0319-P | January 2026
HarmoniaMentis